Wholly-owned subsidiary of Switzerland-based integrated solutions provider for pharma and consumer healthcare – Lonza India announced its plan for Indian market. India is a strategicaly important market for Lonza India with turnover for around 100 million CHF (Swiss Franc) has set the target of doubling its turnover by 2024 with an estimated growth of 15 + per cent.
Lonza India, which offers product portfolio in India and covers an entire life sciences industry has taken up an aggressive expansion plan by announcing corporate offices across the country in the current financial year. The company aims to facilitate bilateral businesses and scientific partnerships with Switzerland, has built a wide network of representations across India.
Lonza started its operations in India in 1997 as a liaison office. The office was involved mainly into sourcing advanced intermediates from India. Lonza came in as a full-fledged sales and commercial organization with the acquisition of Cambrex Bio Products in 2007.